New drug cuts hearing loss in children by 50% after cancer treatment
Hepatoblastoma is a rare type of primary liver cancer that affects young children and is often diagnosed in children under two. During the SIOPEL-6 clinical trial led by
French pharmaceutical company MITEM PHARMA has announced the acquisition of worldwide rights to DESFERAL (deferoxamine), an injectable medicine of major therapeutic interest (MITM) in haematology field, from Novartis.
Integration of smart technologies in pills has instrumented a ground-breaking transformation in the global healthcare marketplace. Initially, consumers and patients were diffident towards invasive surgical procedures and drug
The designation is for the treatment of patients with medium to high folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer who received at least one, but no more than